Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

N/A

2(33.3%)

Phase 2

2(33.3%)

Early Phase 1

1(16.7%)

Phase 1

1(16.7%)

6Total

N/A(2)

Phase 2(2)

Early Phase 1(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05553782Early Phase 1Recruiting

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

Role: collaborator

NCT06322576Phase 2Terminated

177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

Role: collaborator

NCT04883671Not ApplicableRecruiting

Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial

Role: collaborator

NCT05774899Phase 1Recruiting

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Role: collaborator

NCT04706845Completed

Understanding the Burden of ACC Through the Eyes of Patients

Role: collaborator

NCT03999684Phase 2Completed

A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma

Role: collaborator

NCT03319641Not ApplicableCompleted

PSMA-PET Imaging for Advanced ACC/SDC

Role: collaborator

All 7 trials loaded